Trial Profile
An Open-label, Cross-over, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of the Subcutaneous Administration of a Human Plasma-derived C1-esterase Inhibitor in Subjects With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary)
- Indications Hereditary angioedema
- Focus Pharmacokinetics
- Sponsors CSL Behring; Parexel International
- 25 Feb 2019 C1-INH(f) and C4 antigen concentration results from three trials (NCT01912456, NCT01576523, NCT02316353) were presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 27 Feb 2014 New trial record